Source: FirstWord Pharma

Metacrine: Metacrine Reports First-Quarter 2022 Results

SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseas...

Read full article »
Metacrine's Competitors | Metacrine's News | Metacrine's Financials
Stay up-to-date with the latest news on Metacrine
Annual Revenue
$100K-5.0M
Employees
1-25
Michael York's photo - President & CEO of Metacrine

President & CEO

Michael York

CEO Approval Rating

82/100

Read more
Stay up-to-date with the latest news on Metacrine